FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3097242605> ?p ?o ?g. }

• W3097242605 endingPage "18" @default.
• W3097242605 startingPage "17" @default.
• W3097242605 abstract "Background: Children with cancer diagnosis are overall at a higher risk of thrombosis. For a newly diagnosed blood clot or bland thrombus (fibrin clot without neoplastic cells), patients are commonly started on anticoagulants such as unfractionated heparin (UFH) or low molecular weight heparin (LMWH) to prevent further extension and embolization of the clot. In the rare instance that a pediatric patient has a tumor thrombus, defined as the extension of the tumor into a vessel, the role of anticoagulation is less clear. Objective: The aim of this study was to review the data of patients at Texas Children's Hospital (TCH) in the past ten years with a diagnosis of tumor thrombus, the management strategy and role of anticoagulation- its indication, response and complications noted. Methods: Patients under 21 years of age with a finding of tumor thrombus on imaging from 2010-2020 at TCH were identified and their medical records were reviewed. Demographics, location of tumor thrombus, imaging, treatment approach, use of anticoagulation, response to standard treatment (chemotherapy/surgery) and anticoagulation, and outcomes were assessed. This retrospective chart review was approved by the Institutional review board at Baylor College of Medicine. Results: We identified a total of 50 patients with a finding of tumor thrombus in the past ten years treated at our center. Most of them were incidental findings at diagnosis, however there were two patients who initially presented with pulmonary embolism (PE) and later on pathological exam of thrombectomy tissue were found to have relapse of their primary malignancy and tumor thrombus to be the etiology of the PE. Tumor thrombus was mostly identified in the systemic vessels draining the primary tumor. IVC extension was found in 36% of the patients and 24% had an intracardiac tumor thrombus (Table 1). Hepatoblastoma (26%) was most commonly associated with tumor thrombus, followed by Wilms tumor (12%) (Figure 1). Anticoagulation was initiated in 10 patients (20%) with or without standard chemotherapy (rationale for anticoagulation mentioned in Table 2), while remaining patients received the standard treatment for the primary tumor, including chemotherapy, surgery, and/or radiation. In 32.5% of the patients who did not receive anticoagulation, there was a documented decrease in size of tumor thrombus with chemotherapy. Among patients who received anticoagulation, only 2 of the 10 patients showed response to anticoagulation in terms of improvement of symptoms (Improved leg swelling in patient F, improved kidney function with resolution of Renal vein thrombus in patient H). The three patients with pulmonary embolism did not show any resolution of symptoms with initiation of anticoagulation. However, 40% (4/10) patients were noted to have bleeding complications from anticoagulation requiring brief interruption or complete stoppage of anticoagulation (Table 2). On statistical analysis, this association was found to be statistically significant with higher proportion of bleeding events occurring in patients who received anticoagulation (p= 0.01). Conclusion: Children with intravascular extension of solid tumors were not commonly started on anticoagulation at the time of diagnosis despite evidence of extensive tumor thrombus. Furthermore, we observed a significant trend toward higher incidence of bleeding complications after initiation of anticoagulation. We conclude that there is not enough evidence to support routine initiation of anticoagulation in pediatric patients with intravascular extension of solid tumors. Further studies are needed to identify high-risk groups for whom the benefits of anticoagulation may outweigh its risks. We would also emphasize that it is essential to consider a possibility of relapsed disease if patient with a history of malignancy presents with symptoms of thromboembolism and is not responding to anticoagulation as would normally expect. Disclosures No relevant conflicts of interest to declare." @default.
• W3097242605 created "2020-11-09" @default.
• W3097242605 creator A5006630838 @default.
• W3097242605 creator A5020287908 @default.
• W3097242605 creator A5033744972 @default.
• W3097242605 creator A5046343578 @default.
• W3097242605 creator A5049949495 @default.
• W3097242605 creator A5053359551 @default.
• W3097242605 creator A5064788392 @default.
• W3097242605 date "2020-11-05" @default.
• W3097242605 modified "2023-09-28" @default.
• W3097242605 title "Tumor Thrombus- a Single Center Experience with Tumor Thrombus and Role of Anticoagulation" @default.
• W3097242605 doi "https://doi.org/10.1182/blood-2020-141868" @default.
• W3097242605 hasPublicationYear "2020" @default.
• W3097242605 type Work @default.
• W3097242605 sameAs 3097242605 @default.
• W3097242605 citedByCount "1" @default.
• W3097242605 countsByYear W30972426052021 @default.
• W3097242605 crossrefType "journal-article" @default.
• W3097242605 hasAuthorship W3097242605A5006630838 @default.
• W3097242605 hasAuthorship W3097242605A5020287908 @default.
• W3097242605 hasAuthorship W3097242605A5033744972 @default.
• W3097242605 hasAuthorship W3097242605A5046343578 @default.
• W3097242605 hasAuthorship W3097242605A5049949495 @default.
• W3097242605 hasAuthorship W3097242605A5053359551 @default.
• W3097242605 hasAuthorship W3097242605A5064788392 @default.
• W3097242605 hasConcept C121608353 @default.
• W3097242605 hasConcept C126322002 @default.
• W3097242605 hasConcept C126838900 @default.
• W3097242605 hasConcept C141071460 @default.
• W3097242605 hasConcept C2776265017 @default.
• W3097242605 hasConcept C2777557582 @default.
• W3097242605 hasConcept C2779399171 @default.
• W3097242605 hasConcept C2780073493 @default.
• W3097242605 hasConcept C2780868729 @default.
• W3097242605 hasConcept C2781362458 @default.
• W3097242605 hasConcept C71924100 @default.
• W3097242605 hasConceptScore W3097242605C121608353 @default.
• W3097242605 hasConceptScore W3097242605C126322002 @default.
• W3097242605 hasConceptScore W3097242605C126838900 @default.
• W3097242605 hasConceptScore W3097242605C141071460 @default.
• W3097242605 hasConceptScore W3097242605C2776265017 @default.
• W3097242605 hasConceptScore W3097242605C2777557582 @default.
• W3097242605 hasConceptScore W3097242605C2779399171 @default.
• W3097242605 hasConceptScore W3097242605C2780073493 @default.
• W3097242605 hasConceptScore W3097242605C2780868729 @default.
• W3097242605 hasConceptScore W3097242605C2781362458 @default.
• W3097242605 hasConceptScore W3097242605C71924100 @default.
• W3097242605 hasIssue "Supplement 1" @default.
• W3097242605 hasLocation W30972426051 @default.
• W3097242605 hasOpenAccess W3097242605 @default.
• W3097242605 hasPrimaryLocation W30972426051 @default.
• W3097242605 hasRelatedWork W120600296 @default.
• W3097242605 hasRelatedWork W1970932404 @default.
• W3097242605 hasRelatedWork W1988855938 @default.
• W3097242605 hasRelatedWork W2032613738 @default.
• W3097242605 hasRelatedWork W2064469817 @default.
• W3097242605 hasRelatedWork W2071839621 @default.
• W3097242605 hasRelatedWork W2091259491 @default.
• W3097242605 hasRelatedWork W2405336434 @default.
• W3097242605 hasRelatedWork W2414309417 @default.
• W3097242605 hasRelatedWork W27503270 @default.
• W3097242605 hasVolume "136" @default.
• W3097242605 isParatext "false" @default.
• W3097242605 isRetracted "false" @default.
• W3097242605 magId "3097242605" @default.
• W3097242605 workType "article" @default.